Moderna says Covid-19 vaccine trial data 'on track' for November

One of the front-runners in the global efforts to acquire a vaccine against Covid-19 said it was on track to report on the preliminary results of its clinical studies in November.

Moderna said early-stage data on the clinical trial was expected during the following month and that two months of safety data would be available in the second half of November.

The latter was the minimum required to file for emergency use authorisation wit the top US health regulator, the Food and Drug Administration.

The US biotechnology outfit also said that it was working with the World Health Organisation on a tiered pricing model for access to its vaccine.

As of 1409 GMT, shares of Moderna were adding 3.17% to $67.82.